Agila, Pfenex sign biosimilar joint venture deal

04/17/2013 | Genetic Engineering & Biotechnology News

Pfenex and Agila Biotech agreed to develop, manufacture and market six biosimilars as part of a joint venture. Pfenex will combine its strain engineering and process development know-how with Agila's biologics production and clinical development expertise. The venture's lead product will be interferon beta-1b, a biosimilar version of multiple sclerosis treatment Betaseron.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care